Loading stock data…
Arbutus Biopharma Corporation (ABUS)
$5.18+0.03 (+0.58%)
After Hours$5.17-0.01 (-0.19%)· Last close Sep 8
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arbutus Biopharma Corporation in the Healthcare sector is trading at $5.18 with a market capitalization of $859M. Wall Street consensus targets $5.53 (1 analysts), implying a +6.7% move over the next 12 months. The stock is currently near its 52-week high of $5.45, remaining 15.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $179.13M↑ | $1.05M↑ | $529,000↓ | $10.74M↑ | $1.76M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $169.12M↑ | -$7.64M↑ | -$8.29M↓ | $1.91M↑ | -$13.03M |
| Net Income | $169.69M↑ | -$3.76M↑ | -$7.74M↓ | $2.52M↑ | -$24.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$859.29M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.24
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
61.77%
Volume
Today's trading volume
5.29M
Recent News
Health Care Roundup: Market Talk
Gain insight on Moderna, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 10. 3% in premarket trading on Friday after the biotechnology company announced plans to repurchase up to $230 million of its common stock through a modified Dutch auction tender offer.
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.